Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 37

1.

Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women.

Chlebowski RT, Anderson GL, Gass M, Lane DS, Aragaki AK, Kuller LH, Manson JE, Stefanick ML, Ockene J, Sarto GE, Johnson KC, Wactawski-Wende J, Ravdin PM, Schenken R, Hendrix SL, Rajkovic A, Rohan TE, Yasmeen S, Prentice RL; WHI Investigators.

JAMA. 2010 Oct 20;304(15):1684-92. doi: 10.1001/jama.2010.1500.

PMID:
20959578
2.

The haunting of medical journals: how ghostwriting sold "HRT".

Fugh-Berman AJ.

PLoS Med. 2010 Sep 7;7(9):e1000335. doi: 10.1371/journal.pmed.1000335.

3.

Partisan perspectives in the medical literature: a study of high frequency editorialists favoring hormone replacement therapy.

Tatsioni A, Siontis GC, Ioannidis JP.

J Gen Intern Med. 2010 Sep;25(9):914-9. doi: 10.1007/s11606-010-1360-7. Epub 2010 Apr 28.

4.

Ghostwriting: the dirty little secret of medical publishing that just got bigger.

PLoS Medicine Editors.

PLoS Med. 2009 Sep;6(9):e1000156. doi: 10.1371/journal.pmed.1000156. Epub 2009 Sep 8. No abstract available.

5.

Self-plagiarism: unintentional, harmless, or fraud?

[No authors listed]

Lancet. 2009 Aug 29;374(9691):664. doi: 10.1016/S0140-6736(09)61536-1. No abstract available.

PMID:
19716942
6.

Provider attributes associated with hormone therapy prescribing frequency.

Spangler L, Reed SD, Nekhyludov L, Grothaus LC, LaCroix AZ, Newton KM.

Menopause. 2009 Jul-Aug;16(4):810-16. doi: 10.1097/GME.0b013e318198e2fd.

7.

Conflicts of interest and disclosure in the American Psychiatric Association's Clinical Practice Guidelines.

Cosgrove L, Bursztajn HJ, Krimsky S, Anaya M, Walker J.

Psychother Psychosom. 2009;78(4):228-32. doi: 10.1159/000214444. Epub 2009 Apr 28.

PMID:
19401623
8.

Breast cancer after use of estrogen plus progestin in postmenopausal women.

Chlebowski RT, Kuller LH, Prentice RL, Stefanick ML, Manson JE, Gass M, Aragaki AK, Ockene JK, Lane DS, Sarto GE, Rajkovic A, Schenken R, Hendrix SL, Ravdin PM, Rohan TE, Yasmeen S, Anderson G; WHI Investigators.

N Engl J Med. 2009 Feb 5;360(6):573-87. doi: 10.1056/NEJMoa0807684.

9.

Attitudes of obstetrician-gynecologists toward the evidence from the Women's Health Initiative hormone therapy trials remain generally skeptical.

Power ML, Anderson BL, Schulkin J.

Menopause. 2009 May-Jun;16(3):500-8. doi: 10.1097/gme.0b013e31818fc36e.

10.

Off-label promotion, on-target sales.

Fugh-Berman A, Melnick D.

PLoS Med. 2008 Oct 28;5(10):e210. doi: 10.1371/journal.pmed.0050210. No abstract available.

11.

Industry-supported meta-analyses compared with meta-analyses with non-profit or no support: differences in methodological quality and conclusions.

Jørgensen AW, Maric KL, Tendal B, Faurschou A, Gøtzsche PC.

BMC Med Res Methodol. 2008 Sep 9;8:60. doi: 10.1186/1471-2288-8-60.

12.

Factors associated with obstetrician-gynecologists' response to the Women's Health Initiative trial of combined hormone therapy.

Power ML, Baron J, Schulkin J.

Med Decis Making. 2008 May-Jun;28(3):411-8. doi: 10.1177/0272989X07312722. Epub 2008 May 13.

PMID:
18480040
13.

Guest authorship and ghostwriting in publications related to rofecoxib: a case study of industry documents from rofecoxib litigation.

Ross JS, Hill KP, Egilman DS, Krumholz HM.

JAMA. 2008 Apr 16;299(15):1800-12. doi: 10.1001/jama.299.15.1800.

PMID:
18413874
14.

Estrogen plus progestin therapy and breast cancer in recently postmenopausal women.

Prentice RL, Chlebowski RT, Stefanick ML, Manson JE, Pettinger M, Hendrix SL, Hubbell FA, Kooperberg C, Kuller LH, Lane DS, McTiernan A, Jo O'Sullivan M, Rossouw JE, Anderson GL.

Am J Epidemiol. 2008 May 15;167(10):1207-16. doi: 10.1093/aje/kwn044. Epub 2008 Mar 27.

15.

Industry influence in the creation of pay-for-performance quality measures.

Rose J.

Qual Manag Health Care. 2008 Jan-Mar;17(1):27-34. doi: 10.1097/01.QMH.0000308635.59108.29.

PMID:
18204375
16.

How the Women's Health Initiative (WHI) influenced physicians' practice and attitudes.

Bush TM, Bonomi AE, Nekhlyudov L, Ludman EJ, Reed SD, Connelly MT, Grothaus LC, LaCroix AZ, Newton KM.

J Gen Intern Med. 2007 Sep;22(9):1311-6. Epub 2007 Jul 18.

17.

The decrease in breast-cancer incidence in 2003 in the United States.

Ravdin PM, Cronin KA, Howlader N, Berg CD, Chlebowski RT, Feuer EJ, Edwards BK, Berry DA.

N Engl J Med. 2007 Apr 19;356(16):1670-4.

18.

TV commercials for prescription drugs: a discourse analytic perspective.

Glinert LH.

Res Social Adm Pharm. 2005 Jun;1(2):158-84.

PMID:
17138473
19.

Cochrane reviews compared with industry supported meta-analyses and other meta-analyses of the same drugs: systematic review.

Jørgensen AW, Hilden J, Gøtzsche PC.

BMJ. 2006 Oct 14;333(7572):782. Epub 2006 Oct 6. Review.

20.

Evolving practice patterns and attitudes toward hormone therapy of obstetrician-gynecologists.

Power ML, Schulkin J, Rossouw JE.

Menopause. 2007 Jan-Feb;14(1):20-8.

PMID:
17019376
Items per page

Supplemental Content

Write to the Help Desk